Phase Ib and expansion study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with metastatic pancreatic cancer

Authors

Kimberly Perez, Harvard University
Koushik Das, Washington University School of Medicine in St. Louis
et al.

Journal

The oncologist

Publication Date

5-8-2023

Volume

28

Issue

5

First Page

425

Last Page

432

Document Type

Open Access Publication

DOI

10.1093/oncolo/oyad002

Rights and Permissions

Kimberly Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson, Matthew B Yurgelun, Wolfram Goessling, Bruce J Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R Pitarresi, Andrew J Aguirre, Michael Needle, Anil K Rustgi, Brian M Wolpin, Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer, The Oncologist, Volume 28, Issue 5, May 2023, Pages 425–432, https://doi.org/10.1093/oncolo/oyad002. https://academic.oup.com/oncolo/article/28/5/425/7046246?login=true. © The Author(s) 2023. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Perez, Kimberly; Das, Koushik; and et al., "Phase Ib and expansion study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with metastatic pancreatic cancer." The oncologist. 28, 5. 425 - 432. (2023).
https://digitalcommons.wustl.edu/oa_4/4702